HER2分子与肿瘤靶向治疗  

HER2 and Tumor Targeting Therapy

作　　者：鲍炜[1] 裘秀春[2] 贾林涛[3] 张立红[1] 王成济[3] 杨安钢[1] 

机构地区：[1]第四军医大学免疫学教研室,西安市710032 [2]第四军医大学附属唐都医院骨科,西安市710038 [3]第四军医大学生物化学与分子生物学教研室,西安市710032

出　　处：《医学分子生物学杂志》2006年第2期129-132,共4页Journal of Medical Molecular Biology

基　　金：国家高技术研究发展计划(863计划)(No.2004AA217071);国家重点基础研究发展计划(973计划)(No.2004CB518805)~~

摘　　要：HER2分子是表皮生长因子受体家族的第二位成员,对细胞的生长、分化及存活有着重要的调节作用,在乳腺癌、卵巢癌、肺腺癌、肾细胞癌中其过表达与否是患者预后的重要指标。研究表明它与表皮生长因子受体家族其他3位成员形成异二聚体,通过多种信号转导途径促进肿瘤的增殖、转移、耐药性的产生,是肿瘤基因治疗的重要靶位点。HER2 molecule is the second member of the epidermal growth factor receptor family and plays an important role in the growth, differentiation, and survival of cells. Its excessive expression has been an important indicator of the prognosis of breast cancer, ovarian cancer, adenocarcinoma of lung, and renal cell carcinoma. Studies suggest that HER2 overexpression on the surface of cell membrane, by forming heterodimer with the other members, promotes the proliferation and metastasis of tumors and increases the resistance of tumors to chemical therapy. HER2 receptor is a potential target for gene therapy. On the basis of further understanding of molecular mechanisms of its tumorigenesis and development, two strategies, HER2-directing and HER2-targeting, are now being used in the HER2-related studies.

关 键 词：HER2分子 表皮生长因子受体 基因治疗 

分 类 号：R730.5[医药卫生—肿瘤]